The efficacy and safety of Anyu Peibo Capsule in the treatment of patients with major depressive disorder in China: study protocol for a randomized placebo-controlled trial

被引：1
|
作者：
Huang, Jingjing [1 ]
Yu, Yimin [1 ]
Jiang, Yi [2 ]
Chen, Wu [2 ]
Li, Yan [1 ]
Shen, Yifeng [1 ]
Zheng, Qingshan [3 ]
Li, Huafang [1 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Mental Hlth Ctr, Sch Med, 600 Wan Ping Nan Rd, Shanghai 200030, Peoples R China
[2] Su Zhou YiHua Biotechnol Co Ltd, Suzhou, Peoples R China
[3] Shanghai Univ Tradit Chinese Med, Shanghai, Peoples R China
来源：
TRIALS | 2021年 / 22卷 / 01期
关键词：
Depression; Anyu Peibo Capsule; Randomized controlled trials; MEDICINAL-PLANTS; GLOBAL IMPRESSION; SCALE; ANTIDEPRESSANT;
D O I：
10.1186/s13063-021-05550-9
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
Background: Major depressive disorder is the second leading cause of years lost to disability worldwide. Anyu Peibo Capsule has been shown to be effective and safe in phase II trials. Methods: This clinical study is a multi-center, randomized, double-blinded, placebo-controlled, parallel-group, phase III trial of Anyu Peibo Capsule in China. The aim is to test whether the administration of Anyu Peibo Capsule compared to placebo improves clinical outcomes in adults (aged 18 to 65 years) with MDD. Patients will receive an 8-week treatment of Anyu Peibo Capsule 1.6 g per day or placebo. The primary outcome will be the change from baseline in the total score for the Montgomery-Asberg Depression Rating Scale at the end of the 8-week treatment. Discussion: The trial aims to provide pivotal evidence for the efficacy and safety of Anyu Peibo Capsule in patients with major depressive disorder.
引用
收藏
页数：9
相关论文
共 50 条
  • [21] Evidence for Efficacy and Tolerability of Vilazodone in the Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial
    Rickels, Karl
    Athanasiou, Maria
    Robinson, Donald S.
    Gibertini, Michael
    Whalen, Heidi
    Reed, Carol R.
    JOURNAL OF CLINICAL PSYCHIATRY, 2009, 70 (03) : 326 - 333
  • [22] Efficacy and Safety of Curcumin in Major Depressive Disorder: A Randomized Controlled Trial
    Sanmukhani, Jayesh
    Satodia, Vimal
    Trivedi, Jaladhi
    Patel, Tejas
    Tiwari, Deepak
    Panchal, Bharat
    Goel, Ajay
    Tripathi, Chandra Bhanu
    PHYTOTHERAPY RESEARCH, 2014, 28 (04) : 579 - 585
  • [23] A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxiine succinate in the treatment of major depressive disorder
    DeMartinis, Nicolas A.
    Yeung, Paul P.
    Entsuah, Richard
    Manley, Amy L.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (05) : 677 - 688
  • [24] Efficacy and safety of flexibly dosed brexpiprazole for the adjunctive treatment of major depressive disorder: a randomized, active-referenced, placebo-controlled study
    Hobart, Mary
    Skuban, Aleksandar
    Zhang, Peter
    Josiassen, Mette Krog
    Hefting, Nanco
    Augustine, Carole
    Brewer, Claudette
    Sanchez, Raymond
    McQuade, Robert D.
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (04) : 633 - 642
  • [25] Efficacy and Safety of tDCS and tACS in Treatment of Major Depressive Disorder: A Randomized, Double-Blind, Factorial Placebo-Controlled Study Design
    Huang, Yuxin
    Shen, Linjie
    Huang, Jia
    Xu, Xianrong
    Wang, Yong
    Jin, Hua
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2021, 17 : 1459 - 1468
  • [26] A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical
    Gaynor, Paula J.
    Gopal, Murali
    Zheng, Wei
    Martinez, James M.
    Robinson, Michael J.
    Marangell, Lauren B.
    CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (10) : 1849 - 1858
  • [27] Efficacy and safety of vilazodone 20 and 40 mg in major depressive disorder: a randomized, double-blind, placebo-controlled trial
    Mathews, Maju
    Gommoll, Carl
    Chen, Dalei
    Nunez, Rene
    Khan, Arif
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (02) : 67 - 74
  • [28] Efficacy and safety of tipepidine as adjunctive therapy in major depressive disorder: A randomized, double-blind, placebo-controlled clinical trial
    Hoobehfekr, Saba
    Moghaddam, Hossein Sanjari
    Shalbafan, Mohammadreza
    Hashemi, Maryam Ghazizadeh
    Pirmoradi, Mohammad Mehdi
    Sakenian, Amirhossein
    Poopak, Amirhossein
    Kashefinejad, Shayan
    Yarahmadi, Masoomeh
    Akhondzadeh, Shahin
    PSYCHIATRY AND CLINICAL NEUROSCIENCES, 2021, 75 (02) : 57 - 62
  • [29] Replication of Scopolamine's Antidepressant Efficacy in Major Depressive Disorder: A Randomized, Placebo-Controlled Clinical Trial
    Drevets, Wayne C.
    Furey, Maura L.
    BIOLOGICAL PSYCHIATRY, 2010, 67 (05) : 432 - 438
  • [30] Efficacy and safety of pentoxifylline combination therapy in major depressive disorder: a randomized, double-blind, placebo-controlled clinical trial
    Farajollahi-Moghadam, Mostafa
    Sanjari-Moghaddam, Hossein
    Hasemi, Maryam Ghazizadeh
    Sanatian, Zahra
    Talaei, Ali
    Akhondzadeh, Shahin
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2021, 36 (03) : 140 - 146
12345